Jordan

Key Insights

1
No psychedelic therapy is approved for patients in Jordan; psilocybin remains outside routine legal medical access under the current narcotics and psychotropics regime.
2
Jordan records 1 psilocybin trial, 0 active studies, and 1 research organisation, making the country a single-site, pre-clinical outlier.
3
Jordan’s notable signal is not scale but visibility: its lone psilocybin footprint places it on the regional map despite minimal domestic trial capacity.
4
Momentum is coming from clinician education rather than regulation, with a 2025 Jordanian survey of 1,985 physicians and medical students exposing a large familiarity gap.

Strictly Illegal

Reimbursed Care Access

Jordan maintains a highly restrictive national drug control regime: most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, ibogaine, ayahuasca, 2C‑X) are treated as controlled/psychotropic substances with criminal penalties and no routine medical reimbursement or authorized clinical treatment access. Ketamine is used within Jordanian healthcare primarily as an anaesthetic in hospitals (medical use), but psychedelic or psychiatric uses are off‑label and not publicly reimbursed; esketamine (Spravato) has no public record of local marketing authorisation or reimbursement. Clinical research activity in Jordan involving ketamine and other substances exists but access outside approved trials is effectively prohibited by the national drugs law and enforcement practice.

Full guide →